FDA PDUFA Date September 28, 2023Not sure why this board has very little following, but this little company with a small float of 21 million shares is about to receive a FDA decision in 2 weeks which could potentially double their share price if they receive approval.
Ocuphire has $40 million in cash and will receive another $10 million in milestone payment from Viatras, their partner, if Nyxol RM (Reversal of Mydriasis) is approved Sept. 28.
Viatris, a global pharma, is paying all costs of commercialization, including any further testing for other applications of Nyxol. They will pay, upon FDA approval and commerialization of Nyxol a double digit Royalty to Ocuphire on "Net Sales".
The share price has been channeling in the $4 range since May, and depending on the FDA decision, should break out either way. I'm expecting approval. Do some DD on this one as it could be a great long term play with exponential share price appreciation.